The latest Synapse news and Synapse media stories

Accel-Heal® EAE offers a potential saving of £495 million to the NHS.

The cost of wound care in the UK is between £5.1 and £4.5 billion a year and with an estimated 2.2 million wounds managed in the NHS annually¹. Latest paper on the cost effectiveness of Accel-Heal shows that its use for the treat..

Japanese patent and new trademarks granted for Accel-Heal® EAE

We are delighted to announce that Accel-Heal's® EAE Japanese patent application has now been granted. Accel-Heal has also been granted trademark in Australia and New Zealand. These significant developments further expand Synapse's growing pat..

British Medical Innovation Signals Hope to the 200,000 Affected by Complex Wounds in the UK

Conservative estimates suggest that there around 200,000 people in the UK affected by complex wounds such as venous leg ulcers, pressure ulcers and diabetic foot ulcers at any one time. Evidence suggests that outcomes for the 190,000 patients aff..

Accel-Heal to be available for clinical prescribing from October 2015

Synapse Electroceutical Ltd, the company behind Accel-Heal is pleased to confirm that Accel-Heal will be listed in the October 2015 edition of the Drug Tariff, and available for clinical prescribing across England & Wales. Speaking abou..

Food and Drug Administration (FDA) 510(k) Clearence

We are pleased to announce that Synapse Electroceutical have been granted 510(k) clearance . John Gildersleeve, Synapse's CEO commented "This marks an exciting development for Synapse in terms of ability to access the US healthcare market and we ..

Therapeutic Goods Administration (TGA) Approval for Accel-Heal in Australia

Synapse Electroceutical - the home of Accel-Heal are very pleased to announce that Accel-Heal has been granted Therapeutic Goods Administration (TGA) approval for Australia. We look forward to working with clinicians and procurement in this terri..

Latest peer reviewed paper - Improving Quality of Life for Patients with Electroceutical Technology

Improving patient quality of life with innovative electroceutical technology; a case series (

Synapse Electroceutical adds its support to calls for an NHS funding debate

Synapse Electroceutical adds its support to calls for an NHS funding debate

Synapse Electroceutical Ltd - the home of Accel-Heal today voiced its support for a panel of experts from the health and social care sector, calling on policy makers to support a national conversation on the funding of the NHS in a letter to the ..

Leading from within the NHS with medical technologies

Synapse Electroceutical Ltd, the home of Accel-Heal welcomed the “Time to think differently, Reforming the NHS from within” Kings Fund report, published earlier this month. We are encouraged to note that the report calls ..

Accel-Heal® and Bromley Healthcare making our health and care system fit for an ageing population.

Synapse Ltd, the home of Accel-Heal®, and Bromley Healthcare welcomed last week’s report from the King’s Fund - Making our health and care system fit for an ageing population. While arguing that the NHS and wider care..

Accel-Heal® now patented in the US

18-Mar-2014 Synapse Ltd - the home of Accel-Heal® is delighted to announce that Accel-Heal®’s US patent application has been allowed and will issue shortly. John Gildersleeve, CEO of Synapse Electroceutical Ltd comme..

We're moving!

Due to business growth and expansion we have outgrown our current premises. Please bear with us while we relocate our business facilities. There will be reduced telephone and email cover on Thursday 30th May and Friday 31st May 2013. From Monday ..

Wound Care Alliance UK welcomes Synapse Micro-Current as a corporate partner

Synapse Micro-Current - the home of Accel-Heal is delighted to announce a corporate sponsorship agreement with Wound Care Alliance UK (, a not-for-profit organisation providing information, advice and guidance for the special..

Wounds UK 2011

Synapse Microcurrent will be on stand 92 this year. There will be opportunities to learn more about Accel-Heal® unit and a chance to hear two Tissue Viability Nurses speaking about their recent experiences of using Accel-Heal® on their patien..

Media Contact - Anita Uti, Marketing and Communications Manager m:+44 (0)1959 569 433